CA3136229A1 - Novel psma specific binding proteins for cancer diagnosis and treatment - Google Patents
Novel psma specific binding proteins for cancer diagnosis and treatment Download PDFInfo
- Publication number
- CA3136229A1 CA3136229A1 CA3136229A CA3136229A CA3136229A1 CA 3136229 A1 CA3136229 A1 CA 3136229A1 CA 3136229 A CA3136229 A CA 3136229A CA 3136229 A CA3136229 A CA 3136229A CA 3136229 A1 CA3136229 A1 CA 3136229A1
- Authority
- CA
- Canada
- Prior art keywords
- psma
- binding protein
- seq
- psma binding
- ubiquitin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19168525.4 | 2019-04-10 | ||
| EP19168525 | 2019-04-10 | ||
| PCT/EP2020/060043 WO2020208083A1 (en) | 2019-04-10 | 2020-04-08 | Novel psma specific binding proteins for cancer diagnosis and treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3136229A1 true CA3136229A1 (en) | 2020-10-15 |
Family
ID=66286079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3136229A Pending CA3136229A1 (en) | 2019-04-10 | 2020-04-08 | Novel psma specific binding proteins for cancer diagnosis and treatment |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12611441B2 (enExample) |
| EP (2) | EP4108680B1 (enExample) |
| JP (1) | JP7498971B2 (enExample) |
| KR (1) | KR102934740B1 (enExample) |
| CN (1) | CN113677698B (enExample) |
| AU (1) | AU2020271959B2 (enExample) |
| BR (1) | BR112021017863A2 (enExample) |
| CA (1) | CA3136229A1 (enExample) |
| IL (1) | IL286791A (enExample) |
| SG (1) | SG11202110940YA (enExample) |
| WO (1) | WO2020208083A1 (enExample) |
| ZA (1) | ZA202108843B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023285164A1 (en) * | 2021-07-13 | 2023-01-19 | Navigo Proteins Gmbh | Affinity ligands for the purification and detection of ubiquitin muteins |
| CN114569744A (zh) * | 2022-03-08 | 2022-06-03 | 安徽淮仁堂药业股份有限公司 | 一种锝前列腺标特异性膜抗原显像剂试剂盒及其制备方法和应用 |
| CN116041435B (zh) * | 2023-02-21 | 2023-07-07 | 浙江农林大学 | 一种具有2019新型冠状病毒主蛋白酶抑制活性的榛仁蛋白衍生肽及其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003035839A2 (en) * | 2001-10-24 | 2003-05-01 | Dgi Biotechnologies, Inc. | Target specific screening andits use for identifying target binders |
| US7749968B2 (en) * | 2002-08-05 | 2010-07-06 | The Johns Hopkins University | Peptides for targeting the prostate specific membrane antigen |
| DE10324447A1 (de) * | 2003-05-28 | 2004-12-30 | Scil Proteins Gmbh | Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin |
| BR112012014417B1 (pt) | 2009-12-14 | 2021-11-09 | Scil Proteins Gmbh | Proteínas ubiquitinas modificadas tendo uma atividade de ligação específica para o extradomínio b de fibronectina |
| WO2012171541A1 (en) | 2011-06-15 | 2012-12-20 | Scil Proteins Gmbh | Human fusion proteins comprising interferons and hetero-dimeric modified ubiquitin proteins |
| EP3253785B1 (en) * | 2015-02-06 | 2019-04-10 | Navigo Proteins Gmbh | Novel egfr binding proteins |
| US20180030140A1 (en) | 2015-02-06 | 2018-02-01 | Navigo Proteins Gmbh | Novel binding proteins comprising a ubiquitin mutein and antibodies or antibody fragments |
| JP7366518B2 (ja) * | 2015-05-06 | 2023-10-23 | ヤンセン バイオテツク，インコーポレーテツド | 前立腺特異的膜抗原結合フィブロネクチンｉｉｉ型ドメイン |
| CN107849147B (zh) * | 2015-07-20 | 2021-09-17 | 纳维格蛋白质有限公司 | 基于二泛素突变蛋白的Her2结合蛋白 |
| JP2018520675A (ja) * | 2015-07-20 | 2018-08-02 | ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＮａｖｉｇｏ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ | ジユビキチン変異タンパク質をベースとした新規結合タンパク質及びその生成方法 |
| WO2017149002A1 (en) * | 2016-03-03 | 2017-09-08 | Navigo Proteins Gmbh | Novel fusion proteins for capturing of cells |
| WO2023285164A1 (en) * | 2021-07-13 | 2023-01-19 | Navigo Proteins Gmbh | Affinity ligands for the purification and detection of ubiquitin muteins |
-
2020
- 2020-04-08 US US17/602,729 patent/US12611441B2/en active Active
- 2020-04-08 EP EP22180667.2A patent/EP4108680B1/en active Active
- 2020-04-08 CN CN202080027745.0A patent/CN113677698B/zh active Active
- 2020-04-08 WO PCT/EP2020/060043 patent/WO2020208083A1/en not_active Ceased
- 2020-04-08 BR BR112021017863A patent/BR112021017863A2/pt unknown
- 2020-04-08 KR KR1020217036594A patent/KR102934740B1/ko active Active
- 2020-04-08 JP JP2021557014A patent/JP7498971B2/ja active Active
- 2020-04-08 EP EP20716487.2A patent/EP3953375B9/en active Active
- 2020-04-08 SG SG11202110940YA patent/SG11202110940YA/en unknown
- 2020-04-08 AU AU2020271959A patent/AU2020271959B2/en active Active
- 2020-04-08 CA CA3136229A patent/CA3136229A1/en active Pending
-
2021
- 2021-09-29 IL IL286791A patent/IL286791A/en unknown
- 2021-11-09 ZA ZA2021/08843A patent/ZA202108843B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3953375C0 (en) | 2023-06-07 |
| AU2020271959A1 (en) | 2021-09-16 |
| EP4108680B1 (en) | 2024-05-01 |
| CN113677698B (zh) | 2025-02-25 |
| WO2020208083A1 (en) | 2020-10-15 |
| JP7498971B2 (ja) | 2024-06-13 |
| JP2022528053A (ja) | 2022-06-08 |
| ZA202108843B (en) | 2023-07-26 |
| BR112021017863A2 (pt) | 2022-01-04 |
| AU2020271959B2 (en) | 2022-09-29 |
| SG11202110940YA (en) | 2021-10-28 |
| EP3953375A1 (en) | 2022-02-16 |
| IL286791A (en) | 2021-10-31 |
| EP4108680A1 (en) | 2022-12-28 |
| US12611441B2 (en) | 2026-04-28 |
| US20220168386A1 (en) | 2022-06-02 |
| EP3953375B1 (en) | 2023-06-07 |
| KR20210150535A (ko) | 2021-12-10 |
| EP3953375B9 (en) | 2023-10-04 |
| CN113677698A (zh) | 2021-11-19 |
| KR102934740B1 (ko) | 2026-03-04 |
| EP4108680C0 (en) | 2024-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2016295024B2 (en) | Her2 binding proteins based on di-ubiquitin muteins | |
| US20260078155A1 (en) | Novel folr1 specific binding proteins for cancer diagnosis and treatment | |
| US12611441B2 (en) | PSMA specific binding proteins for cancer diagnosis and treatment | |
| JP2026031936A (ja) | 線維芽細胞活性化タンパク質（ｆａｐ）のための特異的結合性分子 | |
| US20240218032A1 (en) | Novel human programmed death ligand 1 (pd-l1) specific binding molecules | |
| WO2025125378A1 (en) | Novel serum albumin-binding fusion proteins | |
| US20250388696A1 (en) | Fusion proteins with half life extending domains | |
| EP4161954B1 (en) | Serum stable binding proteins for human her2 for theranostic applications | |
| KR20250090347A (ko) | 프로그램화 사멸 리간드 1 (pd-l1)에 대한 높은 결합 친화도를 갖는 신규한 단백질 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20240213 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250331 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250331 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250707 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20251010 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20251209 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20251209 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251209 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260330 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260330 |